Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 2
2018 6
2019 8
2020 8
2021 7
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Kantarjian H, et al. Among authors: paul s. J Hematol Oncol. 2023 May 2;16(1):44. doi: 10.1186/s13045-023-01444-2. J Hematol Oncol. 2023. PMID: 37131217 Free PMC article. Clinical Trial.
The face of remission induction.
Paul S, Rausch CR, Jabbour EJ. Paul S, et al. Br J Haematol. 2020 Jan;188(1):101-115. doi: 10.1111/bjh.16353. Epub 2019 Dec 12. Br J Haematol. 2020. PMID: 31828798 Free article. Review.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Jabbour E, et al. Among authors: paul s. Cancer. 2021 Jun 15;127(12):2025-2038. doi: 10.1002/cncr.33469. Epub 2021 Mar 19. Cancer. 2021. PMID: 33740268 Free article.
Treating Leukemia in the Time of COVID-19.
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Paul S, et al. Acta Haematol. 2021;144(2):132-145. doi: 10.1159/000508199. Epub 2020 May 11. Acta Haematol. 2021. PMID: 32392559 Free PMC article. Review.
Adult Acute Lymphoblastic Leukemia.
Paul S, Kantarjian H, Jabbour EJ. Paul S, et al. Mayo Clin Proc. 2016 Nov;91(11):1645-1666. doi: 10.1016/j.mayocp.2016.09.010. Mayo Clin Proc. 2016. PMID: 27814839 Review.
Optimizing patient selection for treatment-free remission.
Rausch CR, Paul S. Rausch CR, et al. Among authors: paul s. J Oncol Pharm Pract. 2020 Jul;26(5):1220-1224. doi: 10.1177/1078155220925167. Epub 2020 May 21. J Oncol Pharm Pract. 2020. PMID: 32437235 Review.
34 results